You are here: Home » PTI Stories » National » News
Business Standard

UK, US drugmakers scrap 'futile' Alzheimer's treatment trial

AFP  |  London 

British and American and today said they were ending a large of a that they had been developing together.

The decision to scrap the phase III comes as a major setback in the race to find a cure for the disease, which is the most common form of and affects millions of people around the world.

"We are saddened by this outcome as our researchers are working tirelessly to find a solution for the many people who are impacted by this devastating disease," Menelas Pangalos, executive vice of said in a statement.

"We won't give up on finding a solution for patients," Daniel Skovronsky, of Research Labs added. The two firms had announced a partnership to develop a new drug aimed at combatting in 2014.

They were working on two treatments, one for patients of early Alzheimer's disease, the other for those with mild Alzheimer's Both treatments used a so-called "inhibitor" targeting an enzyme called BACE.

According to the statement, an independent data monitoring committee ruled that both the treatments "were not likely to meet their primary endpoints upon completion and therefore should be stopped for futility".

The statement also said the discontinuation of the trials was not expected to have any financial impact on the firms' outlook for 2018.

systems in Western countries are struggling to deal with Alzheimer's as it is costly to treat sufferers of the incurable which leaves them increasingly reliant on assistance.

US announced in January it was pulling out of research entirely. Swiss giants and Axovant, as well US firm have all tried to come up with the solution to Alzheimer's.

According to the World Organization, some 50 million people around the world have dementia, with Alzheimer's contributing around 60-70 percent of the cases. The number of patients is expected to double by 2030 and to triple by 2050 if no cure is found.

"Although mainly affects older people, it is not a normal part of ageing," the WHO says on its website. "Dementia has a physical, psychological, social, and economical impact, not only on people with dementia, but also on their carers, families and society at large," it adds.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, June 12 2018. 17:41 IST
RECOMMENDED FOR YOU